期刊文献+

Molecular mechanism of Turmeric in the treatment of liver cancer based on network pharmacology

下载PDF
导出
摘要 Objective:The aim of this study was to use network pharmacology to predict the targets and related signaling pathways of turmeric in the treatment of liver cancer.Methods:The active ingredients of turmeric turmeric and their corresponding targets were screened and collected through the traditional Chinese medicine components and systematic Chinese medicine pharmacology database and analysis platform(TCMSP)database.Through the online human Mendelian network(OMIM),the human genome annotation database(Genecards)and the GAD database,the targets related to liver cancer were collected and compared with the targets corresponding to the drug components,the common parts were screened out to obtain the potential target genes that overlap between turmeric and liver cancer.Cytoscape was used to construct the"compound-target"action network,and the protein interaction(PPI)network was constructed through STRING software to screen the key components and key targets of turmeric for the treatment of liver cancer,and the GO enrichment and KEGG enrichment analysis were conducted on the key targets to analyze their potential mechanism of action.Results:There were 15 active components and 45 target genes in the treatment of liver cancer with turmeric turmeric,and the drug-component-target-disease network showed that the key genes mainly included:MAPK1,MAPK3,AKT1,JUN,RELA,BCL2,CASP8,ESR1,ADRB2,etc.GO functional enrichment showed that biological processes and functions were concentrated in cofactor binding,phosphatase binding,amide binding,g-protein-coupled amide receptor activity,antioxidant activity,steroid activity,nuclear receptor activity,transcription factor activity,direct ligand regulation of sequence-specific DNA binding,and steroid hormone receptor activity.KEGG functional enrichment showed that the enriched pathways mainly included hepatitis b,human immunodeficiency virus 1 infection,apoptosis,hepatitis c and some cancer signaling pathways.Conclusion:The role of turmeric in the treatment of liver cancer may be realized through the above molecular mechanism,providing theoretical evidence for subsequent studies and clinical applications.
出处 《Journal of Hainan Medical University》 2020年第22期41-46,共6页 海南医学院学报(英文版)
基金 CSCO Traditional Chinese Medicine Cancer Research Fund(No.Y-L2018-002)
  • 相关文献

参考文献5

二级参考文献93

  • 1陆占国,郭红转,封丹.芫荽茎叶精油成分及清除DPPH自由基能力研究[J].食品与发酵工业,2006,32(8):24-27. 被引量:67
  • 2邢美玉,李波.紫丁香叶制剂治疗流行性出血性结膜炎[J].中西医结合眼科杂志,1996,14(1):30-30. 被引量:7
  • 3郝彩琴,杜晓峰,庄世宏,马柏林,张兴.小花假泽兰精油化学成分及其抑菌活性初步研究[J].西北植物学报,2007,27(10):2097-2103. 被引量:14
  • 4Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2):87-108.
  • 5International Agency for Reseawh on Cancer. GLOBOCAN 2012: estimated t'ancer incidence, mortality and prevalence worldwide in 2012,2014[ EB/OL]. [ 2014-12-16]. http://globocan.iarc.fr.
  • 6.l'eii,'()M i'rkif-DM, Macle,,na,, R, et al. Cancer registration principles and methods IARC Sci Pub No.95 [ M ]. Lyon: IARC, 1991:101-107.
  • 7Parkin DM, Chert VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19 [ J ]. l.yon: IARC, 1994:35-49.
  • 8Parkin DM, Bray F. Evaluation of data quality in the cancer registry. : principles and methxls Part I1. Completeness[ J ]. Eur J Cancer, 2009, 45 ( 5 ) : 756-764.
  • 9Bray F, Pu'kin DM. Evaluation of data quality in the cmlcer registry : principles and methods. Part 1: comparability, validity and limeliness[ J ]. Eur J Cancer, 2(108, 45(5) :747-755.
  • 10Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003- 2005: a population-based study [J]. lnt J Cancer. 2015. 136 (8) : 1921-1930.

共引文献116

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部